Is Cohance Lifesciences a Good Buy After Its Q1 FY27 Results?

The Cohance Lifesciences share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Cohance Lifesciences is formerly Suven Pharmaceuticals, a pharma CDMO and specialty ingredients company following its merger with Cohance Lifesciences, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 435 crore, down 22.9% year on year, while the company reported a net loss of Rs 45 crore. That combination of numbers is exactly what this article breaks down, along with what it means for the Cohance Lifesciences share price from here.

This piece works through the quarter's financial highlights, the business factors behind the numbers, where the Cohance Lifesciences share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Cohance Lifesciences Q1 FY27 Financial Highlights

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 435 crore	Rs 563 crore	-22.9%
EBITDA	Rs 13 crore	Rs 126 crore	-89.4%
Operating Margin	3.2%	21.5%	NA
Profit Before Tax	-Rs 43 crore	Rs 63 crore	-168.3%
Net Profit / (Loss)	-Rs 45 crore	Rs 46 crore	-197.4%

Cohance Lifesciences Q1 FY27 Performance Analysis

Check Cohance Lifesciences Fundamentals on Univest Screener

Revenue declined 22.9% for the quarter, which was not offset by cost control, and the pharmaceutical CDMO and specialty ingredients business will need a stronger showing next quarter to reverse the trend.

The quarter's most important number is the swing to a net loss of Rs 45 crore, a reversal from the profit reported a year earlier. The revenue trend does not offset this either, and the Cohance Lifesciences share price should be judged on when profitability is likely to return rather than on the topline trend.

On a sequential basis, revenue moved down 29.6% sequentially from Rs 617 crore in the March 2026 quarter and the net loss moved down 643.8% sequentially from Rs 8.31 crore in the prior quarter, giving a fuller picture of the trend behind the Cohance Lifesciences share price than the year on year comparison alone.

Key Business Factors in Q1 FY27

Revenue Trend

Cohance Lifesciences' revenue declined 22.9% year on year this quarter, taking the quarterly base to Rs 435 crore in a pharmaceutical CDMO and specialty ingredients business that remains sensitive to demand and pricing cycles that ultimately feed through to the Cohance Lifesciences share price.

Margin Movement

EBITDA fell to Rs 13 crore from Rs 126 crore, and operating margin slipped to 3.2% from 21.5% a year earlier, pointing to cost or pricing pressure that management will need to manage through the rest of FY27.

Balance Sheet Position

Cohance Lifesciences carries a low debt-to-equity ratio of 0.10, giving it a conservative balance sheet heading into the rest of FY27.

Valuation Context

Cohance Lifesciences does not carry a meaningful PE multiple this quarter given its current earnings, so investors should lean on revenue and book value trends instead of the price-to-earnings ratio when assessing the Cohance Lifesciences share price.

Dividend Details

No interim dividend was declared alongside Cohance Lifesciences' Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Cohance Lifesciences share price for income should watch the company's announcements around its next annual results for any dividend decision.

Cohance Lifesciences Share Price Outlook for FY27

Cohance Lifesciences' path back to profitability is the central question for FY27. Revenue growth is a positive signal, but until the company demonstrates it can convert that growth into profit again, the Cohance Lifesciences share price is likely to stay sensitive to every quarterly update.

Investors should track cost trends and any management commentary on when profitability is expected to normalise, since that timeline will likely matter more to the Cohance Lifesciences share price than revenue growth alone.

Cohance Lifesciences Stock Performance

Download the Univest iOS App or Univest Android App to track Cohance Lifesciences' live share price and get daily stock updates.

The Cohance Lifesciences share price was trading around Rs 443 as results season played out in late August 2026, roughly 57.4% below its 52-week high of Rs 1,039 and well above its 52-week low of Rs 267.

The Cohance Lifesciences share price has likely already absorbed some of this quarter's disappointment, but further downside is possible if the next results confirm the same trend rather than a one-off. On profitability ratios, the company reports a return on equity of 5.05% and a book value of around Rs 102 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Profitability Risk

The quarter's profit trend is the clearest risk here. Until Cohance Lifesciences shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.

Sector and Demand Risk

As a pharmaceutical CDMO and specialty ingredients business, Cohance Lifesciences' results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Cohance Lifesciences share price well before the next result.

Execution Risk

Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

Conclusion

Cohance Lifesciences' swing to a net loss of Rs 45 crore in Q1 FY27 is the standout number from this result, with revenue also under pressure. The Cohance Lifesciences share price is best approached cautiously until the company shows a credible path back to profitability, and this quarter alone does not make a strong case to buy.

Frequently Asked Questions on Cohance Lifesciences Q1 FY27 Results

What were Cohance Lifesciences' Q1 FY27 results?

Ans. Cohance Lifesciences reported Q1 FY27 revenue of Rs 435 crore, down 22.9% year on year, with a net loss of Rs 45 crore.

Is Cohance Lifesciences a good buy after its Q1 FY27 results?

Ans. Cohance Lifesciences' profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.

What is the Cohance Lifesciences share price today?

Ans. The Cohance Lifesciences share price was trading around Rs 443 in late August 2026, about 57.4% below its 52-week high of Rs 1,039 and well above its 52-week low of Rs 267.

What is Cohance Lifesciences' revenue and profit for Q1 FY27?

Ans. Cohance Lifesciences reported revenue of Rs 435 crore and a net loss of Rs 45 crore for the quarter ended June 30, 2026.

Did Cohance Lifesciences declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Cohance Lifesciences' Q1 FY27 results. Investors should track the company's next annual results for any dividend announcement.

Why does Cohance Lifesciences not have a meaningful PE ratio?

Ans. Cohance Lifesciences does not carry a meaningful price-to-earnings ratio currently because of its recent earnings performance. Investors should use revenue and book value trends instead when assessing the stock.

What are the key risks for Cohance Lifesciences investors right now?

Ans. The quarter's profit trend is the clearest risk here. Until Cohance Lifesciences shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results. Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

What is Cohance Lifesciences' promoter shareholding?

Ans. Promoter shareholding data for Cohance Lifesciences was not fully available for this quarter and should be checked on the company's official filings.